A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
Hung-Hsien ChiangChuan-Mo LeeTsung-Hui HuChao-Hung HungJing-Houng WangSheng-Nan LuHsueh-Chou LaiWen-Pang SuChia-Hsin LinCheng-Yuan PengChien-Hung ChenPublished in: Liver international : official journal of the International Association for the Study of the Liver (2018)
The combination of FIB-4 and AFP levels at 12 months of treatment is a useful marker for predicting the development of HCC, cirrhotic events and mortality in compensated cirrhotic patients with CHB who are receiving ETV therapy.